Global Diseases, Global Patents and Differential Treatment in WTO Law
Tapen Sinha () and
Bradly J Condon
Additional contact information
Bradly J Condon: ITAM, Mexico
Law and Economics from University Library of Munich, Germany
As of January 1, 2005, all developing country members of the WTO are required to implement the WTO Agreement on Trade Related Intellectual Property Rights (TRIPS). We analyze the issue of access to patented medicine to treat global and neglected diseases in developing countries in the context of WTO law. We present legal and economic arguments that support balancing the rights of producers and users on a market-by- market basis and argue against taking a uniform approach globally. We conclude that global patent rights are not necessary to provide research incentives to pharmaceutical firms to invent treatments for global and neglected diseases. We develop an analytical framework for assessing special and differential treatment of developing countries in WTO law and apply this framework to TRIPS. We then propose a formula for assessing the correct balance between the rights of producers and users on a market-by-market basis.
Keywords: WTO; TRIPS; AIDS; Chapter 6; HIV; Index Construction (search for similar items in EconPapers)
JEL-codes: K (search for similar items in EconPapers)
New Economics Papers: this item is included in nep-int and nep-law
Note: Type of Document - pdf; pages: 50
References: Add references at CitEc
Citations Track citations by RSS feed
Downloads: (external link)
This item may be available elsewhere in EconPapers: Search for items with the same title.
Export reference: BibTeX
RIS (EndNote, ProCite, RefMan)
Persistent link: https://EconPapers.repec.org/RePEc:wpa:wuwple:0502003
Access Statistics for this paper
More papers in Law and Economics from University Library of Munich, Germany
Bibliographic data for series maintained by EconWPA ().